NCT00390234 · OUTCOME

Incidence of Disease Stabilization, as Measured by Progression-free Survival at 6 Months (Leiomyosaroma Group)

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma · Source last updated 2015-12-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: MEDIAN
Unit: months
Interval / dispersion: 95% Confidence Interval
Time frame: 6 months

Groups in this outcome

Treatment (Ziv-aflibercept)

Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. ziv-aflibercept: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Ziv-aflibercept)	40

Reported measurements

Source class 1

Values in months · Interval/dispersion: 95% Confidence Interval
Group	Value	Spread	Lower	Upper	Comment
Treatment (Ziv-aflibercept)	0.17	Not reported	0.06	0.32	Not reported

Complete source fields

classes

categories
measurements
group Id
OG000
lower Limit
0.06
upper Limit
0.32
value
0.17

denoms

counts
group Id
OG000
value
40
units
Participants

dispersion Type

95% Confidence Interval

groups

description
Patients receive ziv-aflibercept IV over 1 hour on day 1. Treatment repeats every 14 days in the absence of disease progression or unacceptable toxicity. ziv-aflibercept: Given IV
id
OG000
title
Treatment (Ziv-aflibercept)

param Type

MEDIAN

reporting Status

POSTED

time Frame

6 months

title

Incidence of Disease Stabilization, as Measured by Progression-free Survival at 6 Months (Leiomyosaroma Group)

type

PRIMARY

unit Of Measure

months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice